Early clinical experience with trifluridine/tipiracil for refractory metastatic colorectal cancer: The ROS study

• Published in: Journal of clinical oncology Vol. 39; no. 15_suppl; p. e15556
• Main Authors: Garcia-Alfonso, Pilar, Muñoz Martín, Andres J., Jimenez-Castro, Jeronimo, Jiménez-Fonseca, Paula, Pericay, Carles, Longo, Federico, Reyna, Carmen, Argiles, Guillem, Gonzalez Astorga, Beatriz, Gomez-Reina, Maria Jose, Ruíz Casado, Ana, Rodriguez-Salas, Nuria, Lopez-Lopez, Rafael, Carmona Bayonas, Alberto, Conde-Herrero, Veronica, Aranda, Enrique
• Format: Journal Article
• Language: English
• Published: 20-05-2021
• ISSN: 0732-183X; 1527-7755
• DOI: 10.1200/JCO.2021.39.15_suppl.e15556

Abstract only
e15556
Background: Trifluridine/tipiracil is currently approved for metastatic colorectal cancer (mCRC) refractory to available therapies. However, there is no consensus on factors that predict treatment outcomes in daily practice. We assessed the early clinical experience with trifluridine/tipiracil in Spain and potential survival markers. Methods: This was a retrospective cohort study of mCRC patients who participated in the trifluridine/tipiracil early clinical experience program in Spain. The primary outcome was overall survival (OS). Associations between OS and patient characteristics were assessed using multivariate Cox regression analyses. Results: A total of 379 patients were included in the study. Trifluridine/tipiracil was administered for a median of 3.0 cycles and discontinued mainly due to disease progression (79.2%). The median OS was 7.9 months, with a 12-month OS rate of 30.5%. Cox analyses revealed that the following variables independently favoured OS: ≤2 metastases, no liver metastasis, alkaline phosphatase < 300 IU, trifluridine/tipiracil dose reductions, and neutrophil/lymphocyte ratio < 5. Grade ≥3 toxicities were reported in 141 (37.2%) patients, including mainly afebrile neutropenia (23.2%), anaemia (12.1%), and thrombocytopenia (5.3%). Conclusions: This study supports the real-life efficacy and safety of trifluridine/tipiracil for refractory mCRC and identifies tumour burden, liver metastasis, alkaline phosphatase, dose reductions, and neutrophil/lymphocyte ratio as survival markers.